April 25, 2017 — Corindus Vascular Robotics Inc. announced a strategic partnership with BLOXR Solutions, provider of radiation protection products designed to reduce exposure for clinicians and patients. The three-year distribution agreement grants Corindus the non-exclusive rights to distribute BLOXR's radiation protection products globally and provides BLOXR with additional reach into the interventional cardiology space. Under the agreement, Corindus may sell the entire BLOXR line, which offers multiple types of protective equipment including aprons, thyroid collars and caps.
Corindus' CorPath System, the first robotic-assisted percutaneous coronary intervention (PCI) platform cleared by the U.S. Food and Drug Administration (FDA), has been shown* to reduce radiation exposure to the primary operator by 95 percent1 by positioning them behind a radiation-shielded interventional workstation. Clinical trials with the CorPath System* have also shown a 15 percent2 reduction in radiation exposure for cath lab staff, which can potentially be further enhanced by the addition of the BLOXR line of lightweight protective apparel. BLOXR XPF apparel, which has the potential to further reduce the orthopedic burden for these critical team members, is a patented, comfortable, lightweight material that can be bent and folded without cracking, provides 0.5mm lead equivalent protection and is guaranteed for three years.
For more information: www.corindus.com
References
1. Weisz, G. et al. Safety and Feasibility of Robotic Percutaneous Coronary Intervention: PRECISE Study. J Am Coll Cardiol. 2013; 61(15):1596-1600.
2. Campbell et al. Staff Exposure to X-ray during PCI: Randomized Comparison of Robotic vs Manual Procedures. Presented at SCAI 2016.
* Studies conducted using CorPath 200 System.
November 14, 2025 
